CRMD logo

CorMedix Inc. (CRMD)

$7.54

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on CRMD

Market cap

$587700203

EPS

2.18

P/E ratio

3.7

Price to sales

1.6

Dividend yield

--

Beta

1.505137

Price on CRMD

Previous close

$8.14

Today's open

$8.05

Day's range

$7.46 - $8.20

52 week range

$6.13 - $14.96

Profile about CRMD

CEO

Joseph Todisco

Employees

82

Headquarters

Parsippany, NJ

Exchange

NASDAQ Global Market

Shares outstanding

77944324

Issue type

Common Stock

CRMD industries and sectors

Healthcare

Biotechnology & Life Sciences

News on CRMD

CRMD Stock Up as Q2 Earnings & Sales Beat on DefenCath, Melinta Gains

CorMedix stock rises 15% after Q2 earnings and revenues beat estimates, driven by solid DefenCath utilization and contributions from the Melinta portfolio.

news source

Zacks Investment Research • Aug 14, 2026

news preview

CorMedix Q2 Earnings Call Highlights

CorMedix NASDAQ: CRMD reported second-quarter 2026 consolidated revenue of $101.9 million and adjusted EBITDA of $58.7 million, while reaffirming its full-year revenue outlook and raising adjusted EBITDA guidance. The company also said it signed a multiyear commercial supply agreement for DefenCath with an additional large dialysis organization, giving it supply agreements with each of the five largest U.S. dialysis providers.

news source

MarketBeat • Aug 13, 2026

news preview

CorMedix Inc. (CRMD) Q2 2026 Earnings Call Transcript

CorMedix Inc. (CRMD) Q2 2026 Earnings Call Transcript

news source

Seeking Alpha • Aug 13, 2026

news preview

Cormedix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Update

‒ Q2 2026 Consolidated Revenue of  $101.9 million ‒ ‒ Q2 2026 Net Income of $26.0 million ; Adjusted EBITDA of $58.7 million ‒ ‒ Company Maintains FY 2026 Revenue and Raises Adjusted EBITDA Guidance ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ PARSIPPANY, N.J.

news source

GlobeNewsWire • Aug 13, 2026

news preview

CorMedix Stock Jumps on Strong DefenCath Sales

CorMedix Inc. (NASDAQ:CRMD) shares are rising on Thursday after the company reported strong second-quarter results. The broader market was also slightly higher, with S&P 500 futures up 0.2%.

news source

Benzinga • Aug 13, 2026

news preview

CorMedix (CRMD) Q2 Earnings and Revenues Top Estimates

CorMedix (CRMD) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.26 per share. This compares to earnings of $0.28 per share a year ago.

news source

Zacks Investment Research • Aug 13, 2026

news preview

CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026

PARSIPPANY, N.J., July 29, 2026 (GLOBE NEWSWIRE) -- CorMedix Therapeutics (Nasdaq: CRMD) today announced that it will report its financial results for the second quarter ended June 30, 2026, before the market opens on Thursday, August 13, 2026, and will host a corporate update conference call at 8:30am Eastern Time.

news source

GlobeNewsWire • Jul 29, 2026

news preview

CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path

CorMedix is shifting from a single-product launch story as DefenCath drives revenue and Rezzayo adds long-term potential despite reimbursement headwinds.

news source

Zacks Investment Research • Jun 30, 2026

news preview

CRMD's Growth Story Expands Beyond DefenCath Into New Trends

CorMedix broadens beyond DefenCath with Melinta assets, Rezzayo potential and cost synergies as reimbursement changes test long-term earnings durability.

news source

Zacks Investment Research • Jun 30, 2026

news preview

Is CRMD Stock a Buy Now After Strong Growth and New Risks?

CorMedix posted surging DefenCath-led revenue and stronger profitability, but reimbursement changes and execution risks could shape the stock's next phase.

news source

Zacks Investment Research • Jun 30, 2026

news preview

¹ Disclosures

Get started with M1

Invest in CorMedix Inc.

Open an M1 investment account to buy and sell CorMedix Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in CRMD on M1